<DOC>
	<DOCNO>NCT02631876</DOCNO>
	<brief_summary>This Phase 3 , open label , randomize study design compare safety efficacy IMGN853 select single-agent chemotherapy ( Investigator 's choice ) woman platinum-resistant FR-alpha positive advance EOC , primary peritoneal cancer and/or fallopian tube cancer .</brief_summary>
	<brief_title>PH3 Study Mirvetuximab Soravtansine v Investigator 's Choice Chemotherapy Women With FRa+ Adv . EOC , Primary Peritoneal Fallopian Tube Cancer</brief_title>
	<detailed_description>Patients randomize either IMGN853 Investigator 's Choice chemotherapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosed advanced epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer Folate receptor alpha positive tumor expression define protocol Patients must platinumresistant ovarian cancer , define progression within 6 month completion minimum four cycle platinumcontaining therapy . Patients must receive least one three prior systemic treatment regimen singleagent chemotherapy appropriate next line treatment Patients must least one lesion meet definition measurable disease RECIST 1.1 Diagnosis clear cell low grade ovarian cancer Patients primary platinumrefractory disease Serious concurrent illness clinically relevant active infection define protocol Prior treatment IMGN853 Women pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Epithelial ovarian cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>IMGN853</keyword>
	<keyword>ADC</keyword>
	<keyword>Antibody drug conjugate</keyword>
	<keyword>ImmunoGen</keyword>
	<keyword>Antibody</keyword>
	<keyword>Folate receptor alpha</keyword>
	<keyword>mirvetuximab soravtansine</keyword>
	<keyword>Phase 3</keyword>
	<keyword>platinum-resistant</keyword>
</DOC>